Aripiprazole Tablet
Product Images NDC 70518-2806

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2806). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Aripiprazole 20mg 70518 2806 01)

Aripiprazole 20 mg tablet packaging label showing a single tablet quantity. The label includes the NDC number 70518-2806-01, manufacturer information (Ascend Labs, LLC, Montvale, NJ), and repackaging details by RemedyRepack Inc. The label advises storing at 20-25°C with excursions permitted and references a package insert for directions.*

FDA Label Image

Aripiprazole 20mg 70518 2806 02

Aripiprazole 20 mg tablet packaging label showing quantity of 30 tablets. The label includes the NDC number 70518-2806-02, manufacturer Ascend Labs, LLC in Montvale, NJ, and states the repackager as RemedyRepack Inc., Indiana, PA. Directions note to see package insert for use and storage instructions are listed.*

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A Kaplan-Meier survival curve chart comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The chart includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A line graph showing the proportion with relapse over days from randomization for two groups: Aripiprazole and Placebo. The x-axis represents days from randomization up to 364 days, and the y-axis indicates the proportion with relapse ranging from 0.0 to 1.0. The chart includes a risk table below the x-axis showing the number of subjects at risk for both Aripiprazole and Placebo groups at various time points. The Aripiprazole group is depicted with a solid line, and the Placebo group with a dashed line.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart showing the fold change and 90% confidence intervals for Dehydro-Aripiprazole under various drug interactions. It compares the AUC and Cmax values with CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs relative to a reference without interacting drug.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A forest plot chart depicting fold change and 90% confidence intervals for pharmacokinetic parameters such as AUC and Cmax of various drugs and compounds, including CYP2D6, CYP2C9, warfarin, omeprazole, lamotrigine, venlafaxine, and others, relative to a reference without interacting drug. The chart shows the change relative to the reference on the x-axis with values ranging from 0.5 to 3.0.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart illustrating fold change and 90% confidence intervals for Aripiprazole comparing various factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis shows change relative to reference values for AUC and Cmax parameters.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A pharmacokinetic chart illustrating the fold change and 90% confidence intervals for dehydro-aripiprazole based on various factors including CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment. The x-axis shows change relative to reference, and data points represent changes in AUC and Cmax for each category.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing the change in area under the curve (AUC) and maximum concentration (Cmax) of aripiprazole relative to a reference (without interacting drug). The chart includes data for CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam). Error bars represent 90% confidence intervals.*

FDA Label Image

Remedy_label (Remedy Label)

Aripiprazole 20 mg tablet label showing quantity of 30 tablets. The label includes the NDC number 70518-2806-00, repackaged by RemedyRepack Inc., with manufacturing by Ascend Labs, LLC, Montvale, NJ. The label advises storing at 20-25°C with permitted excursions and states the product is for prescription use only.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure of aripiprazole depicted as a skeletal formula showing the arrangement of atoms and bonds in the molecule.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier curve graph showing the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole (solid blue line) and placebo (dashed red line). The graph includes numbers of subjects at risk at several time points for both groups, illustrating a lower relapse proportion in the Aripiprazole group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.